STOCK TITAN

Vanguard realignment; no Alkermes (NASDAQ: ALKS) shares reported

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Alkermes PLC Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Alkermes PLC common stock and 0% of the class. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries report holdings separately.

The amendment is a disclosure of ownership status and reorganization-related reporting changes; it does not show any current beneficial ownership or voting/dispositive power by The Vanguard Group over Alkermes PLC common stock.

Positive

  • None.

Negative

  • None.

Insights

The filing confirms no beneficial ownership by The Vanguard Group.

The filing states Amount beneficially owned: 0 and Percent of class: 0%, indicating Vanguard reports no current beneficial stake in Alkermes PLC common stock. The statement includes the January 12, 2026 realignment language referencing SEC Release No. 34-39538.

Cash-flow treatment and any prior holdings are not disclosed here; subsequent filings by Vanguard subsidiaries may show separate positions if present.

Amendment documents reporting structure changes, not a transaction.

The amendment explains that certain Vanguard subsidiaries now report holdings on a disaggregated basis following an internal realignment under SEC guidance. The filing asserts those subsidiaries pursue the same strategies previously pursued by The Vanguard Group, Inc.

This is a procedural disclosure about reporting attribution; it does not state any sale, acquisition, or change in Alkermes PLC ownership amount in this excerpt.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

Does The Vanguard Group own Alkermes PLC (ALKS) shares according to this filing?

No—The Vanguard Group reports 0 shares beneficially owned and 0% of the class. The amendment explicitly lists voting and dispositive powers as 0 in Item 4, indicating no beneficial ownership reported here.

What is the significance of the January 12, 2026 realignment mentioned in the filing?

It explains internal reporting changes at Vanguard: certain subsidiaries now report holdings separately under SEC Release No. 34-39538. The filing states these subsidiaries pursue the same investment strategies as before the realignment.

Does this Schedule 13G/A show any recent purchases or sales of ALKS by Vanguard?

No—this amendment reports ownership levels only and shows 0 shares. It does not disclose any transactions, purchases, or sales in the provided excerpt.

Who signed the amendment on behalf of Vanguard and when?

The filing is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 03/26/2026. The signature attests to the reported ownership and disclosures.

Will separate filings from Vanguard subsidiaries show Alkermes holdings?

Possibly—after the internal realignment, certain subsidiaries report holdings separately under SEC Release No. 34-39538. Any subsidiary holdings would appear in their own filings if they hold Alkermes shares.
Alkermes Plc

NASDAQ:ALKS

View ALKS Stock Overview

ALKS Rankings

ALKS Latest News

ALKS Latest SEC Filings

ALKS Stock Data

4.89B
163.30M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 4